Societies and governments face an unprecedented challenge in providing health care for large populations of older people with serious chronic illness and multimorbidity.^[@bibr1-2381468319866451]^ Single-disease-focused decision making within health systems designed to produce acute, episodic care does not appropriately meet the complex needs of older populations with multiple illnesses.^[@bibr1-2381468319866451][@bibr2-2381468319866451][@bibr3-2381468319866451][@bibr4-2381468319866451]--[@bibr5-2381468319866451]^ Projected future cost curves for this population are unsustainable, making reform a policy priority in the United States and internationally.^[@bibr6-2381468319866451],[@bibr7-2381468319866451]^

Palliative care is provided by an interdisciplinary team of specialists in medicine, nursing and psycho-social-spiritual care, serving patients and families facing serious illness.^[@bibr8-2381468319866451]^ It strives to improve patient-centered communication, care planning, and the management of multiple symptoms associated with such illness.^[@bibr8-2381468319866451]^ Palliative care is identified in guidelines as having potential benefits across the trajectory of any serious illness for persons of all ages. The World Health Organization recommends palliative care as applicable from early in the course of all life-limiting diseases,^[@bibr9-2381468319866451]^ and the American Society of Clinical Oncology recommends palliative care concurrently with active treatment from point of metastatic cancer diagnosis regardless of prognosis.^[@bibr10-2381468319866451]^

This expansion of palliative care involvement poses new questions for policy, practice, and evaluation. Previously the target population was generally defined as those entering an end-of-life phase, receiving an intervention conceptualized as withdrawal of futile treatment.^[@bibr11-2381468319866451],[@bibr12-2381468319866451]^ In this context, cost savings from the intervention are inevitable, though modest.^[@bibr13-2381468319866451]^ Evaluating palliative care earlier in the disease course requires more detailed consideration of both intervention, including upstream palliative involvement, and population, including those with multimorbidity and/or noncancer progressive diseases with different trajectories.^[@bibr14-2381468319866451],[@bibr15-2381468319866451]^

Conceptual Framework and Rationale {#section1-2381468319866451}
==================================

Kelley and colleagues propose that the amounts and type of care received by a person with serious illness is a function of clinical need, other individual determinants, patient and family preferences, physician attitudes, and local practice ([Figure 1](#fig1-2381468319866451){ref-type="fig"}).^[@bibr16-2381468319866451]^ Within this framework, palliative care may affect costs of treatment not only by managing pain and other symptoms and reducing futile treatments but also by informing the choices of attending physicians and by involving patients and families in decision making, including goals-of-care discussions and discharge planning.

![Conceptual model for treatment of patients with serious illness.^[@bibr16-2381468319866451]^](10.1177_2381468319866451-fig1){#fig1-2381468319866451}

How palliative care is associated with changing patterns of treatment for people with life-limiting illness outside of the end-of-life phase will necessarily vary given different prognoses, attending specialisms, and treatment regimens, but this variance is not well understood. Where some early research suggested that patterns could not be changed for an intractably complex, multimorbid minority,^[@bibr17-2381468319866451]^ more recent work found that the cost-saving estimates are largest for those with higher numbers of complications^[@bibr18-2381468319866451]^ and comorbidities.^[@bibr19-2381468319866451]^

We interpret these results as indicating that palliative care is at least in part multifaceted decision support. Where patients have a single serious disease and clear prognosis, single-disease-focused care is typically more appropriate (although palliative care may still be beneficial). Multimorbidity brings more concurrent medications with effects, side-effects, and possible interactions, and a wider host of clinical voices through multiple attending specialty teams,^[@bibr20-2381468319866451],[@bibr21-2381468319866451]^ and interdisciplinary decision making may have a greater impact on the course of care. Palliative care may be beneficial for all patients with serious illness but the lack of careful treatment planning in the scenario of multimorbidity makes it more likely the patient will end up in the intensive care unit or receive other interventions that may be burdensome on the patient, futile, and costly.^[@bibr22-2381468319866451]^

From an economic perspective, understanding heterogeneity of treatment effects is critical to optimal allocation of scarce resources.^[@bibr23-2381468319866451][@bibr24-2381468319866451]--[@bibr25-2381468319866451]^ Such analyses are nevertheless rare across health economics^[@bibr26-2381468319866451]^ and in palliative care,^[@bibr27-2381468319866451]^ where most services do not meet staffing recommendations.^[@bibr28-2381468319866451]^ While a difference has been shown in estimated cost savings in cancer and noncancer populations,^[@bibr29-2381468319866451]^ variation across specific noncancer diagnoses has not yet been evaluated. Clarifying treatment effect heterogeneity for noncancer patients can both inform optimal allocation of existing capacity and also contribute to wider understanding of interdisciplinary decision making in care for complex medical illness in the era of multimorbidity.

Aim and Hypotheses {#section2-2381468319866451}
==================

To estimate the association between palliative care and hospital costs by primary diagnosis and multimorbidity for adults with one of six life-limiting conditions: heart failure, respiratory failure including chronic obstructive pulmonary disease (COPD), end-stage liver disease, end-stage kidney disease, selected neurodegenerative conditions including dementia, and HIV/AIDS.

We hypothesized that in comparisons by diagnosis, estimated cost savings would be greatest for end-stage liver disease, where prognosis is poor and high-intensity treatments are commonplace. We hypothesized that in comparisons by multimorbidity, estimated cost savings would be greatest for those with multimorbidity, where interdisciplinary decision making is most effective in changing treatment choices from usual care.

Methods {#section3-2381468319866451}
=======

Study Design and Participants {#section4-2381468319866451}
-----------------------------

Previously we have reported a systematic database search (to December 2017) and meta-analysis of six hospital palliative care cost studies.^[@bibr29-2381468319866451]^ In this article, we pooled data from four of these studies,^[@bibr30-2381468319866451][@bibr31-2381468319866451][@bibr32-2381468319866451]--[@bibr33-2381468319866451]^ excluding the others for enrolling only cancer patients^[@bibr34-2381468319866451]^ and due to data access restrictions.^[@bibr35-2381468319866451]^

The four pooled studies share methodological fundamentals: retrospective cohort studies of routinely collected data for single-index hospital admissions that (excluding cancer patients) enrolled adults with one of six diagnoses identified via hospital *International Classification of Diseases, Ninth Revision* (ICD-9), codes at admission. These diagnoses were identified as palliative care relevant for research purposes: progressive, life-limiting conditions often accompanied by high symptom burden, frequent hospitalizations, and decisions about further treatment.^[@bibr30-2381468319866451],[@bibr36-2381468319866451]^ Patients admitted for trauma or organ transplant were excluded. Data were collected from 2002 to 2015; study characteristics are summarized in [Table 1](#table1-2381468319866451){ref-type="table"}.^[@bibr29-2381468319866451]^

###### 

Four Datasets Included in Meta-Analysis: Overview of Study Characteristics

![](10.1177_2381468319866451-table1)

                                  Morrison (2008)^[@bibr30-2381468319866451]^                  Morrison (2011)^[@bibr31-2381468319866451]^                                 McCarthy (2015)^[@bibr32-2381468319866451]^   May (2017)^[@bibr33-2381468319866451]^
  ------------------------------- ------------------------------------------------------------ --------------------------------------------------------------------------- --------------------------------------------- ----------------------------------------------------------------
  *Study summary*                                                                                                                                                                                                        
  Design                          Retrospective cohort                                         Retrospective cohort                                                        Retrospective cohort                          Retrospective cohort
  Data sources                    Routine hospital databases                                   Routine hospital databases; Medicaid patients only                          Routine hospital databases                    Routine hospital databases
  Control for bias                Propensity scores                                            Propensity scores                                                           Propensity scores                             Propensity scores
  Years of data collection        2001--2004                                                   2003--2007                                                                  2011--2014                                    2007--2015
  State(s) (all studies US)       California; Kentucky; Minnesota; New York; Ohio; Wisconsin   New York                                                                    Texas                                         Virginia
  Primary dx: Heart failure       17,095                                                       1689                                                                        6513                                          2877
  Primary dx: Neurodegenerative   2759                                                         125                                                                         171                                           262
  Primary dx: COPD                14,897                                                       2365                                                                        5367                                          118
  Primary dx: Kidney failure      4777                                                         809                                                                         730                                           66
  Primary dx: HIV/AIDS            2003                                                         580                                                                         435                                           50
  Primary dx: Liver failure       5279                                                         1513                                                                        2316                                          508
  Total subjects                  46,810                                                       7081                                                                        15,532                                        3881
  Received PC ≤3 days             3%                                                           3%                                                                          3%                                            5%
  Live discharges                 92%                                                          94%                                                                         96%                                           98%
  Sites (\#)                      8                                                            4                                                                           5                                             1
  Setting                         Five Community and 3 academic hospitals                      One community hospital, 2 academic medical centers, 1 safety-net hospital   Four Community and 1 academic hospital        High-volume tertiary care medical center and academic hospital

COPD, chronic obstructive pulmonary disease; ICD-9, *International Classification of Diseases, Ninth Revision.*

*Sampling:* All four studies used a fixed list of life-limiting illnesses identified as relevant for palliative care research purposes. See [Appendix Part 1](https://journals.sagepub.com/doi/suppl/10.1177/2381468319866451) for ICD codes. In original reporting, three studies removed long-stay outliers from their samples ex ante;^[@bibr30-2381468319866451][@bibr31-2381468319866451]--[@bibr32-2381468319866451]^ one study also included all eligible patients on each admission during the study period (so some subjects had multiple admissions).^[@bibr32-2381468319866451]^ We retained long-stay outliers as their removal has been shown to bias results and inflate treatment effect estimates.^[@bibr17-2381468319866451]^ We did not include subjects on a return admission to minimize possible bias from double-counting of some patients. Instead we accessed original study data in each case, excluded those with a primary cancer diagnosis, and retained all other subjects for their first admission in the study period where they met the baseline criteria (i.e., an ICD-9 code as listed in the [appendix](https://journals.sagepub.com/doi/suppl/10.1177/2381468319866451)).

In primary analysis, we grouped patients into six groups according to primary diagnosis. In secondary analysis, we divided each of the six diagnostic groups into two according to multimorbidity status (≤1 \|2≤ on the Elixhauser index^[@bibr37-2381468319866451]^).

Variables {#section5-2381468319866451}
---------

### Dependent Variable {#section6-2381468319866451}

In primary analysis, outcomes of interest were total direct hospital costs and length of stay (LOS) in hospital. In secondary analysis, we focused on total direct hospital costs only.

Direct costs were extracted from each hospital site's accounting database at the time of the original studies and reflect the specific dollar cost to the hospital of relevant staffing, equipment, pharmaceuticals, and procedures for each subject.^[@bibr38-2381468319866451]^ Excluded were indirect costs, sometimes known as overheads, which reflect the patient's "share" of fixed costs such as hospital buildings, facilities, and maintenance. We included only direct costs as those that the intervention could plausibly have affected in the window of analysis (e.g., by reducing tests or shortening stay and so staff burden). Inclusion of indirect costs risks inflating estimated treatment effects because in accounting systems these are typically calculated as a proportion of direct costs. Thus, an intervention that reduces direct costs will also appear in analysis to have reduced indirect costs, but these will still exist from the hospital to pay from other sources. We standardized all costs to 2015, the final year of data collection, using the Consumer Price Index.^[@bibr39-2381468319866451]^

### Intervention Variable {#section7-2381468319866451}

Primary exposure variable was binary: Did the subject receive a palliative care consultation within three days of admission?

Palliative care consultations are delivered by a physician-led interdisciplinary team including a nurse and social worker. The team becomes involved in the care of patients at the invitation of the attending physician and advises on pain and symptom management, and initiates goals-of-care discussions and discharge planning.^[@bibr40-2381468319866451],[@bibr41-2381468319866451]^ Palliative care team involvement was identified by stand-alone databases operated by programs.^[@bibr42-2381468319866451]^

### Additional Independent Variables {#section8-2381468319866451}

Additional independent variables were those factors collected at admission that we hypothesized could be associated with both treatment and outcome, and that were available in all four datasets. These are listed in [Table 2](#table2-2381468319866451){ref-type="table"}. We calculated comorbidity count on the Elixhauser index, a list of 31 chronic conditions: congestive heart failure; cardiac arrhythmia; valvular disease; pulmonary circulation; peripheral vascular disorders; uncomplicated hypertension; complicated hypertension; paralysis; other neurologic disorders; chronic pulmonary disease; uncomplicated diabetes; complicated diabetes; hypothyroidism; renal failure; liver disease; peptic ulcer disease; AIDS/HIV; lymphoma; metastatic cancer; solid tumor without metastasis; rheumatoid arthritis; coagulopathy; obesity; weight loss; fluid/electrolyte disorders; blood loss anemia; deficiency anemia; alcohol abuse; drug abuse; psychoses; and depression. Conditions were identified via ICD-9 code in hospital records. Each condition is dichotomous (absent = 0 \| present = 1), and each subject's Elixhauser total is the sum of 31 dichotomous scores.^[@bibr37-2381468319866451]^

###### 

Baseline Characteristics and Summary Outcomes, by Primary Diagnosis

![](10.1177_2381468319866451-table2)

                             All              Heart             Neuro            COPD             Liver            Kidney           HIV/AIDS
  ------------------- ----------------- ----------------- ----------------- --------------- ----------------- ----------------- -----------------
  N                        73,304            28,174             3317            22,747            9616              6382              3068
  *Baseline*                                                                                                                    
  Age                     64.8 (66)         70.8 (15)         71.1 (17)        64.6 (16)        54.1 (13)         61.2 (17)         44.1 (10)
  Male                       47%               47%               44%              41%              57%               50%               66%
  Medicaid                   20%               12%               10%              19%              33%               22%               60%
  Medicare                   60%               72%               73%              60%              29%               64%               20%
  Elixhauser              3.0 (1.7)         3.3 (1.7)         2.0 (1.4)        2.8 (1.6)        2.8 (1.7)         3.4 (1.6)         2.4 (1.6)
  Walraven                7.4 (7.2)         8.6 (7.3)         3.8 (5.3)        5.5 (6.1)       10.2 (8.6)         7.9 (6.3)         5.1 (7.5)
  *Treatment*                                                                                                                   
  Received PC                8%                8%                12%              5%               7%                8%                14%
  PC day                  9.4 (13)          9.4 (14)           6.0 (8)         8.2 (12)         10.4 (13)         11.6 (17)         12.0 (13)
  *Outcomes*                                                                                                                    
  Direct costs (\$)    10,483 (22,350)   10,913 (23,416)   10,330 (17,034)   7420 (13,557)   15,111 (33,125)   11,062 (22,146)   13,688 (24,818)
  LOS                     8.2 (10)          8.3 (10)          9.7 (11)          7.0 (8)         8.8 (11)          8.9 (12)          10.6 (12)
  Died                       7%                7%                8%               4%               10%               8%                11%

COPD, chronic obstructive pulmonary disease; LOS, length of stay; PC, palliative care.

For continuous/count variables: Mean (standard deviation). Medicare/Medicaid: Principal payer; reference case = any other payer. Elixhauser/Walraven: illness burden indices.^[@bibr37-2381468319866451],[@bibr43-2381468319866451]^ Received PC: had a palliative care consultation at any time during admission; PC day: days from admission to first palliative care interaction. Direct costs: total direct cost of index admission. LOS: length of stay in hospital during index admission. Died: during index admission.

Additionally we calculated each subject's propensity for in-hospital mortality based on characteristics at admission using the van Walraven index.^[@bibr43-2381468319866451]^ This modifies the Elixhauser scoring system, attributing each of the 31 conditions a score (range: −7 to +12) that captures each condition's association with hospital death. In the context of well-known problems controlling for mortality in seriously-ill populations with routine data,^[@bibr44-2381468319866451]^ we considered this a superior approach to excluding or explicitly controlling for observed hospital death in the sample due to endogeneity concerns.^[@bibr45-2381468319866451]^

Finally, we included year of admission as a predictor in regression and in propensity score calculation to control for practice changes over time of the studies.

### Bias {#section9-2381468319866451}

We balanced treatment and comparison groups on observed covariates hypothesized to be associated with treatment and outcome ([Table 2](#table2-2381468319866451){ref-type="table"}).^[@bibr46-2381468319866451],[@bibr47-2381468319866451]^ Prior to estimating treatment effects, we assessed common support, balance of covariates within propensity score blocks, and balance of covariates after weighting the sample.^[@bibr48-2381468319866451]^ For details, see [Appendix Part 2](https://journals.sagepub.com/doi/suppl/10.1177/2381468319866451). Within each analytic subsample defined by diagnosis and/or multimorbidity, we calculated new propensity scores using the covariate balancing propensity score method, creating inverse-probability-of-treatment-weights from the estimated propensity score for analyses.^[@bibr49-2381468319866451]^ Propensity scores were calculated in R.^[@bibr50-2381468319866451]^

### Statistical Methods {#section10-2381468319866451}

#### Estimating treatment effect for a given sample {#section11-2381468319866451}

We used generalized linear models (gamma distribution, log link) and bootstrapped standard errors (1000 reps) to estimate the marginal average treatment effect on the treated (ATET), the average effect of treatment on the outcome of interest for those who received PCC, holding all other values constant and applying sample-specific propensity score weights. Regressions were performed in Stata (version 12).^[@bibr51-2381468319866451]^ For all tests, *P* \< 0.05 was considered as significant ex ante.

#### Comparing treatment effect estimates {#section12-2381468319866451}

Each regression output evaluating association between treatment and outcome represented an ATET distribution which has a reported mean, bootstrapped standard error, 95% confidence interval (CI), and sample size. To compare the estimates for each of the six disease groups, we compared the ATET distributions using one-way analysis of variance (ANOVA), which takes into account the mean, variance, and sample size of each ATET distribution. Where the ANOVA test statistic was significant, post hoc Tukey HSD tests were used to assess each of the head-to-head comparisons for significance (15 head-to-head comparisons for each outcome of interest).

To compare the treatment effect estimates of single disease (Elixhauser index ≤ 1) and multimorbid (2 ≤ Elixhauser index) subgroups within each diagnosis, we compared the ATET distributions using independent *t* tests.

### Funding {#section13-2381468319866451}

The lead author was supported by the International Access, Rights and Empowerment Fellowship Program, which was funded by Grant 24611 from The Atlantic Philanthropies.

Results {#section14-2381468319866451}
=======

Descriptive and Outcome Data {#section15-2381468319866451}
----------------------------

There were 73,304 in the analytic sample ([Table 2](#table2-2381468319866451){ref-type="table"}), of whom 28,174 (38%) had a primary diagnosis of heart disease, 3317 (5%) had a neurodegenerative condition, 22,747 (31%) had COPD, 9616 (13%) had liver disease, 6382 (9%) had kidney disease, and 3068 (4%) had HIV/AIDS.

Summary outcome measures are also presented in [Table 2](#table2-2381468319866451){ref-type="table"}. In the overall sample, 8% (range: 5% to 14%) received palliative care during the admission and 7% (4% to 11%) died before discharge. Mean total direct costs of admission were \$10,483 and average LOS was 8.2 days.

Main Results {#section16-2381468319866451}
------------

Primary analyses are presented in [Table 3](#table3-2381468319866451){ref-type="table"}. Palliative care had a statistically significant association with lower total direct costs for five diagnostic groups: heart failure (ATET: −2666; 95% CI: −3440 to −1892), neurodegenerative (−3523; −4394 to −2651), COPD (−1613; −2217 to −1009), kidney failure (−3589; −5132 to −2045), and liver failure (−7574; −9232 to −5916). Each of these diagnostic groups also had a statistically significant association with reduced LOS. The equivalent associations for HIV/AIDS were not significant in either case. Additional details of regression output are provided in [Appendix Part 3](https://journals.sagepub.com/doi/suppl/10.1177/2381468319866451).

###### 

Primary Analyses: Estimated Treatment Effects on Direct Costs (US\$) and LOS (Days), by Primary Diagnosis

![](10.1177_2381468319866451-table3)

                                              Total Direct Costs (\$)   LOS (Days)                                                                                             
  ------------------- -------- -------- ----- ------------------------- -------------------- --------------------------------------- -------------------- -------------------- --------------------------------
  Heart failure       28,174   27,340   834   **−2666**                 **−3440 to −1892**   ***F*(5, 1953) = 5.3, *P* \< 0.0005**   **−1.20**            **−1.77 to −0.64**   *F*(5, 1953) = 2.2, *P* = 0.05
  Neurodegenerative   3317     3124     193   **−3523**                 **−4394 to −2651**   **−2.76**                               **−3.40 to −2.12**                        
  COPD                22,747   22,332   415   **−1613**                 **−2217 to −1009**                                           **−1.13**            **−1.66 to −0.60**   
  Kidney failure      6382     6226     156   **−3589**                 **−5132 to −2045**                                           **−2.32**            **−3.18 to −1.46**   
  HIV/AIDS            3068     2944     124   −2564                     −6311 to 1184                                                −1.07                −2.97 to 0.84        
  Liver failure       9616     9379     237   **−7574**                 **−9232 to −5916**                                           **−1.57**            **−2.36 to −0.78**   

ATET, average treatment effect on the treated; CG, comparison group, including all other subjects; CI, confidence interval; COPD, chronic obstructive pulmonary disease; LOS, length of stay; TG, treatment group, receiving palliative care within three days of admission.

The ANOVA test statistic evaluating difference between estimates by diagnostic group was significant for costs but not for LOS. Post hoc evaluation in [Table 4](#table4-2381468319866451){ref-type="table"} finds that the estimated association was statistically significantly larger for liver failure than each of the other five diagnoses, and that no other disease-to-disease comparison was significantly different.

###### 

Tukey HSD Post Hoc Evaluations for ANOVA Test in Primary Cost Analysis
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                      Heart Failure versus       Neurodegen versus        COPD versus                Kidney versus            HIV/AIDS versus
  ------------------- -------------------------- ------------------------ -------------------------- ------------------------ -------------------------
  Neurodegenerative   −857; *P* = 0.93                                                                                        
  COPD                +1053; *P* = 0.62          +1910; *P* = 0.36                                                            
  Kidney failure      −923; *P* = 0.93           −66; *P* = 0.99          −1976; *P* = 0.41                                   
  HIV/AIDS            +102; *P* = 0.99           +959; *P* = 0.98         −951; *P* = 0.96           +1025; *P* = 0.97        
  Liver failure       **−4908; *P* \< 0.0005**   **−4051; *P* = 0.003**   **−5961; *P* \< 0.0005**   **−3985; *P* = 0.007**   **−5010; *P* = 0.0007**

COPD, chronic obstructive pulmonary disease.

*p*\<0.05

Secondary analyses are presented in [Table 5](#table5-2381468319866451){ref-type="table"}. For COPD and liver failure, which each exhibited a significant association in the overall sample ([Table 3](#table3-2381468319866451){ref-type="table"}), the estimated cost association was only significant for multimorbid subsamples and not single-disease groups. In comparing the results by multimorbidity status within each disease group, significant differences were observed for only two of the six diagnostic groups: liver failure and neurodegenerative. In each case the estimated cost association was larger for the multimorbid group than those with a single disease.

###### 

Secondary Analyses: Estimated Treatment Effects on Direct Costs, by Primary Diagnosis and Elixhauser Total (ET).
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  Diagnosis                    All (*N*)   CG (*n*)   TG (*n*)   ATET (\$)   95% CI                *t* Test
  ------------------- -------- ----------- ---------- ---------- ----------- --------------------- ----------------------------------------
  Heart failure       ET ≤ 1   3813        3715       98         **−2407**   **−3308 to −1507**    *t* = 0.6; df = 832; *P* = 0.54
                      2 ≤ ET   24,361      23,625     736        **−2787**   **−3644 to −1931**    
  Neurodegenerative   ET ≤ 1   1320        1245       75         **−2427**   **−3376 to −1477**    ***t* = 2.3; df = 191; *P* = 0.02**
                      2 ≤ ET   1997        1879       118        **−4424**   **−5869 to −2978**    
  COPD                ET ≤ 1   4440        4380       60         −990        −2366 to 387          *t* = 1.0; df = 413; *P* = 0.32
                      2 ≤ ET   18,307      17,952     355        **−1771**   **−2467 to −1076**    
  Kidney failure      ET ≤ 1   739         729        10         **−4268**   **−6710 to −1827**    *t* = 0.4; df = 154; *P* = 0.71
                      2 ≤ ET   5643        5497       146        **−3705**   **−5356 to −2054**    
  HIV/AIDS            ET ≤ 1   970         943        27         −731        −2602 to 1140         *t* = 1.0; df = 122; *P* = 0.33
                      2 ≤ ET   2098        2001       97         −3655       −9261 to 1951         
  Liver failure       ET ≤ 1   2216        2175       41         −2780       −5657 to 96           ***t* = 3.7; df = 235; *P* \< 0.0005**
                      2 ≤ ET   7400        7204       196        **−9330**   **−11244 to −7416**   

ATET, average treatment effect on the treated; CG, comparison group, including all other subjects; CI, confidence interval; COPD, chronic obstructive pulmonary disease; TG, treatment group, receiving palliative care within three days of admission.

*p*\<0.05

Discussion {#section17-2381468319866451}
==========

Key Results {#section18-2381468319866451}
-----------

In estimating palliative care's association with lower hospital costs for adults with life-limiting illnesses other than cancer, heterogeneity in treatment effect estimates was observable. The intervention was associated with reduced costs and LOS for five of six primary diagnoses ([Table 3](#table3-2381468319866451){ref-type="table"}), and the cost-saving estimate was significantly larger for liver failure than for other disease groups ([Table 4](#table4-2381468319866451){ref-type="table"}). The treatment effect estimate was also significantly larger for multimorbid patients than those with a single disease, where the primary diagnosis was liver failure or neurodegenerative ([Table 5](#table5-2381468319866451){ref-type="table"}). For COPD and liver failure, the intervention was only significantly associated with lower costs for those with multimorbidity.

These primary results were in line with our hypotheses. The estimate that cost savings were significantly larger for liver disease than other diagnostic groups may be explained by that group's high propensity for intensive care unit admission and other invasive treatments. Notably, liver disease was both the youngest and the highest cost diagnostic group ([Table 2](#table2-2381468319866451){ref-type="table"}), implying higher intensity treatment under usual care and greater potential for changing patterns of treatment. The significant association with reduced LOS for each diagnostic group with a significant cost-saving estimate was consistent with prior studies and our hypotheses that palliative care does not simply reduce intensity of treatment or futile care, but changing patterns and expediting hospital discharge, possibly through goals-of-care discussions and transition planning.^[@bibr52-2381468319866451]^

The secondary finding that there was an interaction between primary disease and multimorbidity---savings were estimated to be greater by multimorbidity status for some disease groups but not others---demonstrates further the presence of heterogeneity in estimates, and the need for better understanding of who benefits most from palliative care when. The lack of significant association by multimorbidity for four disease groups was not in line with our hypotheses, suggesting that the relationships are more complicated; it is not simply that palliative care is more effective the higher the disease burden. Rather, treatment effect may be contingent on both primary diagnosis and multimorbidity count, and potentially the presence or interaction of specific combinations of conditions.

Limitations {#section19-2381468319866451}
-----------

This study uses observational data so causation cannot be claimed. While we controlled for some observed confounders using propensity score weights, other important confounders (e.g., race) were excluded as not available in all data sets. Additionally unobserved confounding may be an important factor in results. We could not identify a valid instrumental variable in these data to manage unobserved confounding. Propensity scores may exacerbate bias from unobserved confounding.^[@bibr53-2381468319866451]^ We therefore re-ran our primary analyses without propensity scores. Results were substantively similar. For full details see [Appendix Part 4](https://journals.sagepub.com/doi/suppl/10.1177/2381468319866451).

We specified our exposure variable as palliative care within 3 days of admission. No clinical guidelines exist to inform such a cutoff but incorporating timing is essential to the accuracy and usefulness of effect estimates as well as reducing risk of a false negative.^[@bibr34-2381468319866451]^ Patients may vary in responsiveness to palliative care involvement and preferences for changing treatment pathways at different times in an admission and optimally the treatment variable would be modelled continuously to capture this. Moreover, there are factors hidden to investigators that were observable to physicians during clinical practice, for example, likelihood that certain treatments will lead to poor outcomes for certain patients. Reported associations may therefore be overestimated, if patients who received palliative care were more likely to benefit that those who did not in ways that our data do not capture. We used our chosen approach on the basis that, all else held constant, earlier consults will have a larger effect.^[@bibr54-2381468319866451]^ Our results were robust to alternative cut-offs.

We used routinely collected data, which leads to crude classification of patient diagnosis and need. Optimal approaches to identifying treatment effect heterogeneity in this context require multidimensional classification of need according to age, diagnosis, multimorbidity, and physical and cognitive impairments. Additionally, the data were collected over a long time period during which there has been rapid growth in palliative care activity in large US hospitals as well as changing attitudes among primary attending physicians toward palliative care.^[@bibr55-2381468319866451]^ Future studies examining these questions would optimally extract data from a larger population (more hospitals, or systems) in a shorter time period to maximize representativeness of current practice. However, this analysis represents the first such of its kind and advances the evidence on this research question.

Our analyses were restricted to single index hospital admissions from the provider perspective. In the context of recommendations for palliative care from point of diagnosis, future research must investigate economic effects across the disease trajectory.^[@bibr56-2381468319866451]^ Nevertheless, hospital costs account for most health care utilization among the seriously ill and are therefore a valid subject of enquiry in their own right.^[@bibr57-2381468319866451],[@bibr58-2381468319866451]^ We included only direct costs in our outcome of interest, and since indirect costs are a function of direct costs this decision does not substantively effect results. Long-run analyses of how treatment patterns change hospital costs should incorporate indirect costs since in principle in the long run these costs can be saved, for example, by closing buildings, redeploying staff.

We examined only association between treatment and costs, but full economic evaluation incorporates intervention effect on costs and on outcomes.^[@bibr56-2381468319866451]^ From an economic perspective, scarce palliative care capacity should be prioritized for those groups for whom cost-effects are largest only on an assumption that outcome effects are equal across diagnostic groups. We are not aware of any study to examine heterogeneity of clinical outcomes, and this work is essential before evidence of heterogeneity could be used as a basis for clinical practice guidelines.

Interpretation and Future Research {#section20-2381468319866451}
----------------------------------

Our rationale for pursuing this enquiry was twofold. First, understanding heterogeneity of treatment effect estimates maximizes the usefulness of health economic studies to inform service planning and resource allocation,^[@bibr23-2381468319866451][@bibr24-2381468319866451]--[@bibr25-2381468319866451]^ and relevant evidence is currently limited in palliative care. Second, such evidence as does exist in palliative care points to an interesting and potentially powerful insight: that interdisciplinary decision making has the most impact among the most complex patients, who account disproportionately for costs while experiencing poor outcomes and unmet need in systems originally designed to provide acute, episodic care.^[@bibr22-2381468319866451]^

With regard to staff and service planning within hospital settings, we estimated significant cost savings for five different diagnostic groups for whom palliative care referral rates are currently low as well as substantive heterogeneity of estimated association between treatment and costs. Expanding palliative care access according to national guidelines could reduce costs of serious illness patients in hospital. In assessing the association between disease burden and estimated treatment effect, we found that it was not simply the case that multimorbid patients were associated with larger treatment estimates than single-disease patients. Future research is required to understand when and for whom to provide palliative care interventions improve patterns of treatment.

Such research could examine the interaction of specific diseases and combinations of diseases, and how observed effects vary by age given the well-known complexities of delineating years lived, years to death, and costs in the last year of life.^[@bibr59-2381468319866451],[@bibr60-2381468319866451]^ However, this will require very large samples, particularly for diagnoses where prompt palliative care referral at admission is less common. Recent advances in machine learning may indicate the most efficient way to progress this research agenda.^[@bibr27-2381468319866451],[@bibr61-2381468319866451]^ The particular drivers of estimated savings, with respect to both expedited discharge and reduced intensity of care, would also be valuable. Given that palliative care is a multifaceted intervention and different models of care have reported different treatment effect estimates,^[@bibr33-2381468319866451],[@bibr62-2381468319866451]^ such analyses must delineate the effect of components, which also may vary by population.^[@bibr25-2381468319866451]^

Perhaps most important in an era of multimorbidity during which people will live months and years with life-limiting illness is to widen the scope of enquiry. This requires moving beyond single index hospital admissions to establish how interventions---and specific components of interventions---affect costs and outcomes across the disease trajectory.

Conclusion {#section21-2381468319866451}
==========

In estimating palliative care's association with hospital costs for adults with noncancer diagnoses, substantive heterogeneity in treatment effect estimates was observable. Improving outcomes and lowering costs for people with serious medical illness is widely recognized as a policy priority, yet understanding of when and for whom interventions change patterns of care remains formative. Further research is required to inform allocation of scarce capacity currently and consider future application of interdisciplinary decision making alongside usual care in treatment of complex medical illness.
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